FGLDS1
MCID: FNG006
MIFTS: 61

Feingold Syndrome 1 (FGLDS1)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Feingold Syndrome 1

MalaCards integrated aliases for Feingold Syndrome 1:

Name: Feingold Syndrome 1 57 25 72 29 6
Feingold Syndrome 57 12 73 20 43 58 36 29 13 15
Oculodigitoesophagoduodenal Syndrome 57 25 20 72 44 70
Oded Syndrome 57 12 25 20 58
Digital Anomalies with Short Palpebral Fissures and Atresia of Esophagus or Duodenum 57 12 58 72
Microcephaly-Oculo-Digito-Esophageal-Duodenal Syndrome 57 12 20 72
Brunner-Winter Syndrome 20 43 58
Mmt Syndrome 57 20 72
Fglds1 57 58 72
Microcephaly and Digital Abnormalities with Normal Intelligence 57 72
Microcephaly-Digital Anomalies-Normal Intelligence Syndrome 12 58
Oculo-Digito-Esophageal-Duodenal Syndrome 12 58
Moded Syndrome 12 58
Moded 57 72
Fglds 12 58
Oded 57 72
Digital Anomalies with Short Palpebral Fissures and Atresia of Esophagus or Duodenum Type 1 58
Digital Anomalies with Short Palpebral Fissures and Atresia of Esophagus, or Duodenum 20
Microcephaly-Intellectual Disability-Tracheoesophageal Fistula Syndrome Type 1 58
Microcephaly, Mental Retardation, and Tracheoesophageal Fistula Syndrome 57
Microcephaly-Intellectual Disability-Tracheoesophageal Fistula Syndrome 58
Microcephaly-Oculo-Digito-Esophageal-Duodenal Syndrome Syndrome Type 1 58
Microcephaly Mental Retardation and Tracheoesophageal Fistula Syndrome 72
Microcephaly-Mesobrachyphalangy-Tracheoesophageal Fistula Syndrome 43
Microcephaly-Digital Anomalies-Normal Intelligence Syndrome Type 1 58
Microcephaly-Oculo-Digito-Esophageal-Duodenal Syndrome Syndrome 58
Microcephaly-Oculo-Digito-Esophageal-Duodenal Syndrome; Moded 57
Microcephaly-Oculo-Digito-Esophageal-Duodenal Syndrome 43
Oculo-Digito-Esophageal-Duodenal Syndrome Type 1 58
Oculodigitoesophagoduodenal Syndrome; Oded 57
Oculo-Digito-Esophagoduodental Syndrome 43
Brunner-Winter Syndrome Type 1 58
Feingold Syndrome, Type 1 39
Feingold Syndrome Type 1 58
Moded Syndrome Type 1 58
Oded Syndrome Type 1 58
Mmt Type 1 58
Mmt 58
Fs1 58
Fs 58

Characteristics:

Orphanet epidemiological data:

58
feingold syndrome
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Neonatal;
feingold syndrome type 1
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal; Age of death: adult;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
feingold syndrome 1:
Inheritance autosomal dominant inheritance


GeneReviews:

25
Penetrance The penetrance for major features of fs1, especially digital abnormalities, appears to be 100% but clinical expression can vary considerably.

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare bone diseases
Developmental anomalies during embryogenesis


Summaries for Feingold Syndrome 1

MedlinePlus Genetics : 43 Feingold syndrome is a disorder that affects many parts of the body. There are two types of Feingold syndrome, distinguished by their genetic cause; both types have similar features that can vary among affected individuals.Individuals with Feingold syndrome type 1 or type 2 have characteristic abnormalities of their fingers and toes. Almost all people with this condition have a specific hand abnormality called brachymesophalangy, which refers to shortening of the second and fifth fingers. Other common abnormalities include fifth fingers that curve inward (clinodactyly), underdeveloped thumbs (thumb hypoplasia), and fusion (syndactyly) of the second and third toes or the fourth and fifth toes.Additional common features of both types of Feingold syndrome include an unusually small head size (microcephaly), a small jaw (micrognathia), a narrow opening of the eyelids (short palpebral fissures), and mild to moderate learning disabilities. Less often, affected individuals have hearing loss, short stature, or kidney or heart abnormalities.People with Feingold syndrome type 1 are frequently born with a blockage in part of their digestive system called gastrointestinal atresia. In most cases, the blockage occurs in the esophagus (esophageal atresia) or in part of the small intestine (duodenal atresia). Individuals with type 2 do not have gastrointestinal atresias.

MalaCards based summary : Feingold Syndrome 1, also known as feingold syndrome, is related to duodenal atresia and esophageal atresia. An important gene associated with Feingold Syndrome 1 is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Nicorandil and Indapamide have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and bone, and related phenotypes are microcephaly and brachydactyly

Disease Ontology : 12 A syndrome characterized by variable combinations of microcephaly, limb malformations, esophageal and duodenal atresias, and learning disability/mental retardation.

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 1305 Definition Feingold syndrome (FS), also known as oculo-digito-esophageal-duodenal (ODED) syndrome, is a rare inherited malformation syndrome characterized by microcephaly, short stature and numerous digital anomalies and is comprised of two subtypes: FS type 1 (FS1) and FS type 2 (FS2) (see these terms). FS1 is by far the most common form while FS2 has only been reported in 3 patients and has the same clinical characteristics as FS1, apart from the absence of gastrointestinal atresia and short palpebral fissures.

OMIM® : 57 Feingold syndrome is an autosomal dominant disorder characterized by variable combinations of microcephaly, limb malformations, esophageal and duodenal atresias, and learning disability/mental retardation. Hand and foot abnormalities may include hypoplastic thumbs, clinodactyly of second and fifth fingers, syndactyly (characteristically between second and third and fourth and fifth toes), and shortened or absent middle phalanges. Cardiac and renal malformations, vertebral anomalies, and deafness have also been described in a minority of patients (summary by Teszas et al., 2006). (164280) (Updated 05-Apr-2021)

KEGG : 36 Feingold syndrome (FGLDS) is characterized by limb malformations, microcephaly, esophageal/duodenal atresias, and learning disability. Feingold syndrome is caused by mutations in MYCN and inherited as an autosomal dominant trait. Recently, individuals sharing the skeletal abnormalities of FGLDS but lacking mutations in MYCN, were found to harbour deletions of the MIR17HG gene. These individuals share many of the characteristics of FGLDS except for gastrointestinal atresia. The condition was termed Feingold syndrome type 2 (FGLDS2).

UniProtKB/Swiss-Prot : 72 Feingold syndrome 1: A syndrome characterized by variable combinations of esophageal and duodenal atresias, microcephaly, learning disability, mental retardation, and limb malformations. Hand and foot abnormalities may include hypoplastic thumbs, clinodactyly of second and fifth fingers, syndactyly (characteristically between second and third and fourth and fifth toes), and shortened or absent middle phalanges. Cardiac and renal malformations, vertebral anomalies, and deafness have also been described.

Wikipedia : 73 Feingold syndrome (also called oculodigitoesophagoduodenal syndrome) is a rare autosomal dominant... more...

GeneReviews: NBK7050

Related Diseases for Feingold Syndrome 1

Diseases in the Feingold Syndrome 1 family:

Feingold Syndrome 2

Diseases related to Feingold Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 duodenal atresia 31.0 RNU4ATAC MYCN FOXF1
2 esophageal atresia 30.8 MYCN GLI3 FOXF1 CHD7
3 vacterl association 30.3 MTHFSD FOXF1 CHD7
4 anus, imperforate 30.2 MTHFSD GLI3 FOXF1 CHD7
5 feingold syndrome 2 11.0
6 dentin dysplasia, type i 11.0
7 nodular ganglioneuroblastoma 10.4 MYCNOS MYCN
8 patent ductus arteriosus 1 10.4
9 bunion 10.4
10 heart septal defect 10.3 RNU4ATAC MIR17 CHD7
11 malignant ovarian surface epithelial-stromal neoplasm 10.3 MIR92A1 MIR23B MIR17
12 pancreas, annular 10.3 MTHFSD FOXF1
13 ovary epithelial cancer 10.3 MIR92A1 MIR23B MIR17
14 chromosomal deletion syndrome 10.3 MIR19B1 MIR19A MIR17
15 microphthalmia, syndromic 3 10.3 MTHFSD FOXF1 CHD7
16 pallister-hall syndrome 10.2 MTHFSD GLI3 FOXF1
17 microcephaly 10.2
18 intestinal benign neoplasm 10.2 MIR20A MIR18A MIR17
19 gastrointestinal system benign neoplasm 10.2 MIR20A MIR18A MIR17
20 rhabdomyosarcoma 10.2
21 central nervous system cancer 10.2 MYCN MIR19A MIR18A MIR17
22 rectum cancer 10.2 MIR92A1 MIR20A MIR17
23 brachydactyly 10.2
24 upper respiratory tract disease 10.2 MIR363 MIR20A MIR19A MIR17
25 physical disorder 10.2 RNU4ATAC GLI3 CHD7
26 bladder disease 10.2 MIR23B MIR19B1 MIR18A MIR17
27 nervous system cancer 10.2 MYCN MIR23B MIR19A MIR18A MIR17
28 thyroid gland anaplastic carcinoma 10.2 MIR19A MIR18A MIR17
29 male reproductive system disease 10.2 MIR92A1 MIR23B MIR20A MIR18A MIR17
30 autonomic nervous system neoplasm 10.2 MYCN MIR20A MIR17
31 atrial heart septal defect 10.2 RNU4ATAC FOXF1 CHD7
32 lymphatic system cancer 10.2 MIR92A1 MIR23B MIR20A MIR18A MIR17
33 respiratory system cancer 10.2 MIR20A MIR19A MIR18A MIR17
34 lymphatic system disease 10.2 MIR92A1 MIR23B MIR20A MIR18A MIR17
35 colonic disease 10.2 MIR92A1 MIR23B MIR20A MIR18A MIR17
36 learning disability 10.2
37 stomach disease 10.2 MIR92A1 MIR23B MIR20A MIR18A MIR17
38 male reproductive organ cancer 10.2 MIR92A1 MIR23B MIR20A MIR18A MIR17
39 prostate disease 10.1 MIR92A1 MIR23B MIR20A MIR18A MIR17
40 peripheral nervous system neoplasm 10.1 MYCN MIR20A MIR17
41 large intestine cancer 10.1 MIR92A1 MIR23B MIR20A MIR18A MIR17
42 lymphoma, non-hodgkin, familial 10.1 MYCN MIR92A1 MIR23B MIR20A MIR17
43 endocrine gland cancer 10.1 MIR92A1 MIR23B MIR20A MIR18A MIR17
44 thoracic cancer 10.1 MIR92A1 MIR23B MIR20A MIR18A MIR17
45 gastrointestinal system cancer 10.1 MIR92A1 MIR23B MIR20A MIR18A MIR17
46 urinary system disease 10.1 MIR23B MIR20A MIR19B1 MIR18A MIR17
47 hepatitis c 10.1
48 opiate dependence 10.1
49 mesenchymal cell neoplasm 10.1
50 esophageal disease 10.1 MIR23B MIR18A MIR17

Graphical network of the top 20 diseases related to Feingold Syndrome 1:



Diseases related to Feingold Syndrome 1

Symptoms & Phenotypes for Feingold Syndrome 1

Human phenotypes related to Feingold Syndrome 1:

58 31 (show top 50) (show all 71)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 microcephaly 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0000252
2 brachydactyly 58 31 hallmark (90%) Very frequent (99-80%) HP:0001156
3 clinodactyly of the 5th finger 58 31 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0004209
4 short palpebral fissure 58 31 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0012745
5 deviation of the 2nd finger 58 31 hallmark (90%) Very frequent (99-80%) HP:0009468
6 intellectual disability 58 31 frequent (33%) Frequent (79-30%),Very rare (<4-1%) HP:0001249
7 depressed nasal bridge 58 31 frequent (33%) Frequent (79-30%) HP:0005280
8 abnormal facial shape 58 31 frequent (33%) Frequent (79-30%) HP:0001999
9 anteverted nares 58 31 frequent (33%) Frequent (79-30%) HP:0000463
10 short stature 58 31 frequent (33%) Frequent (79-30%),Very rare (<4-1%) HP:0004322
11 micrognathia 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000347
12 specific learning disability 58 31 frequent (33%) Frequent (79-30%) HP:0001328
13 external ear malformation 58 31 frequent (33%) Frequent (79-30%) HP:0008572
14 hallux valgus 58 31 frequent (33%) Frequent (79-30%) HP:0001822
15 short thumb 58 31 frequent (33%) Frequent (79-30%) HP:0009778
16 toe syndactyly 58 31 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0001770
17 esophageal atresia 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0002032
18 2-3 toe syndactyly 58 31 very rare (1%) Frequent (79-30%) HP:0004691
19 short middle phalanx of the 5th finger 58 31 frequent (33%) Frequent (79-30%) HP:0004220
20 short middle phalanx of the 2nd finger 58 31 frequent (33%) Frequent (79-30%) HP:0009577
21 4-5 toe syndactyly 58 31 very rare (1%) Frequent (79-30%) HP:0004692
22 sensorineural hearing impairment 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000407
23 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
24 abnormal form of the vertebral bodies 58 31 occasional (7.5%) Occasional (29-5%) HP:0003312
25 horseshoe kidney 58 31 occasional (7.5%) Occasional (29-5%) HP:0000085
26 conductive hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000405
27 patent ductus arteriosus 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001643
28 interrupted aortic arch 58 31 occasional (7.5%) Occasional (29-5%) HP:0011611
29 vesicoureteral reflux 58 31 occasional (7.5%) Occasional (29-5%) HP:0000076
30 hydronephrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000126
31 tricuspid atresia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011662
32 abnormality of the spleen 58 31 occasional (7.5%) Occasional (29-5%) HP:0001743
33 oral cleft 58 31 occasional (7.5%) Occasional (29-5%) HP:0000202
34 annular pancreas 58 31 occasional (7.5%) Occasional (29-5%) HP:0001734
35 duodenal atresia 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002247
36 renal dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000110
37 tricuspid stenosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010446
38 nephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000123
39 multiple muscular ventricular septal defects 58 31 occasional (7.5%) Occasional (29-5%) HP:0011625
40 anal atresia 58 31 very rare (1%) Very rare (<4-1%) HP:0002023
41 jejunal atresia 58 31 very rare (1%) Very rare (<4-1%) HP:0005235
42 high palate 31 HP:0000218
43 hearing impairment 31 HP:0000365
44 wide nasal bridge 31 HP:0000431
45 thick vermilion border 31 HP:0012471
46 everted lower lip vermilion 31 HP:0000232
47 prominent occiput 31 HP:0000269
48 low-set ears 31 HP:0000369
49 epicanthus 31 HP:0000286
50 short toe 31 HP:0001831

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Head And Neck Head:
prominent occiput
small anterior fontanelle
microcephaly (79% of cases)

Head And Neck Ears:
low-set ears
hearing loss
posteriorly angulated ears

Prenatal Manifestations Amniotic Fluid:
polyhydramnios

Abdomen Gastrointestinal:
tracheoesophageal fistula
esophageal atresia
duodenal atresia

Abdomen Pancreas:
annular pancreas

Head And Neck Mouth:
high-arched palate
prominent lips

Neurologic Central Nervous System:
mental retardation
learning disability (90% patients)

Skeletal Hands:
thumb symphalangism
absent/hypoplastic middle phalanx of 2nd finger
absent/hypoplastic middle phalanx of 5th finger

Head And Neck Face:
micrognathia
facial asymmetry
triangular face

Respiratory Larynx:
vocal cord paralysis

Cardiovascular Vascular:
patent ductus arteriosus

Prenatal Manifestations Movement:
decreased fetal movement

Head And Neck Nose:
broad nasal bridge
anteverted nostrils
flat nasal tip

Head And Neck Eyes:
epicanthal folds
short palpebral fissures
upslanting palpebral fissures
narrow palpebral fissures

Abdomen Spleen:
supernumerary spleen
congenital asplenia

Skeletal Feet:
syndactyly of toes 2-3 (56%) and 4-5 (86%)
short toes

Clinical features from OMIM®:

164280 (Updated 05-Apr-2021)

Drugs & Therapeutics for Feingold Syndrome 1

Drugs for Feingold Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 839)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
2
Indapamide Approved Phase 4 26807-65-8 3702
3
Cinacalcet Approved Phase 4 226256-56-0 156419
4
Dipyridamole Approved Phase 4 58-32-2 3108
5
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
6
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
7
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
8
Adenosine Approved, Investigational Phase 4 58-61-7 60961
9
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
10
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
11
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130 64778
12
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
13
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
14
Travoprost Approved Phase 4 157283-68-6 5282226
15
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
16
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
17
Brinzolamide Approved Phase 4 138890-62-7 68844
18
Timolol Approved Phase 4 26839-75-8 33624 5478
19
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
20
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
21
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
22
Netilmicin Approved, Investigational Phase 4 56391-56-1 6857423 441306
23
Dibekacin Approved Phase 4 34493-98-6
24
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
25
Vorapaxar Approved Phase 4 618385-01-6
26
Nevirapine Approved Phase 4 129618-40-2 4463
27
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Lopinavir Approved Phase 4 192725-17-0 92727
30
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
31
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
32
Metformin Approved Phase 4 657-24-9 4091 14219
33
Glimepiride Approved Phase 4 93479-97-1 3476
34
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
35
Insulin glargine Approved Phase 4 160337-95-1
36
Amlodipine Approved Phase 4 88150-42-9 2162
37
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
38
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
39
Zopiclone Approved Phase 4 43200-80-2 5735
40
Zidovudine Approved Phase 4 30516-87-1 35370
41
Ofloxacin Approved Phase 4 82419-36-1 4583
42
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
43
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
44
Simvastatin Approved Phase 4 79902-63-9 54454
45
Losartan Approved Phase 4 114798-26-4 3961
46
Liraglutide Approved Phase 4 204656-20-2 44147092
47
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
48
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
49
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
50
Adapalene Approved Phase 4 106685-40-9 60164

Interventional clinical trials:

(show top 50) (show all 1881)
# Name Status NCT ID Phase Drugs
1 HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial Unknown status NCT03476616 Phase 4 Eplerenone (-based therapy) arm;Valsartan (-based therapy) arm
2 An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
3 Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors Unknown status NCT00752947 Phase 4 moxifloxacin;levofloxacin;metronidazole
4 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
5 Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability Unknown status NCT03890939 Phase 4
6 Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study Unknown status NCT01167062 Phase 4 Tamsulosin Hydrochloride OCAS 0.4 mg
7 Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks Unknown status NCT00988026 Phase 4 Minocycline vs Lymecycline
8 An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections Unknown status NCT03160807 Phase 4 Levofloxacin;Levofloxacin
9 Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria Unknown status NCT01038895 Phase 4 Ramipril;Experimental
10 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
11 Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study Unknown status NCT00716950 Phase 4 valsartan/amlodpine;losartan/amlodpine
12 A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
13 Phase IV Study of Antibacterial Effect on Silver Dressing of NPWT Unknown status NCT02274207 Phase 4
14 The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial Unknown status NCT02835534 Phase 4 rhTNK-tPA;alteplase
15 Phase 4 Study of Desflurane and Sevoflurane That Affect Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum Unknown status NCT01486953 Phase 4 Desflurane;Sevoflurane
16 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
17 Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation. Unknown status NCT01216254 Phase 4
18 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
19 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
20 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
21 What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa Unknown status NCT01044719 Phase 4 Ceftazidime;Tobramycin;Meropenem
22 Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization Unknown status NCT02513004 Phase 4 Ticagrelor;Clopidogrel
23 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
24 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
25 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Unknown status NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
26 PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena Unknown status NCT00526006 Phase 4 esomeprazole
27 Megadyne ACE Incision/Dissection Study Unknown status NCT01175889 Phase 4
28 Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study Unknown status NCT02626117 Phase 4
29 Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole Unknown status NCT00808314 Phase 4 Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT;Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
30 Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia Completed NCT01559753 Phase 4 Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin;compare 8 to15 days of antibiotic treatment
31 Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study Completed NCT02548650 Phase 4 Vorapaxar;Clopidogrel;Aspirin
32 Effect of Dosage Reduction of Glucose-Lowering Multidrug Regimens on the Incidence of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: An Open-Label, Parallel-Group, Randomized, Controlled Trial Completed NCT04237493 Phase 4 Metformin and Glimepiride (Low Dosage);Metformin and Vildagliptin (Low Dosage);Metformin and Insulin Glargine U100 (Low Dosage);Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage);Metformin and Glimepiride (Regular Dosage);Metformin and Vildagliptin (Regular Dosage);Metformin and Insulin Glargine U100 (Regular Dosage);Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)
33 A Five-arm, Randomised, Open Label, Multi-centre, Prospective Study to Compare the Efficacy, Safety and Tolerability of Metoprolol XL Plus Amlodipine Combination (Selomax TM) With Metoprolol XL and Amlodipine as Individual Components in Management of Hypertension in Indian Patients. Completed NCT00819104 Phase 4 Metoprolol XL 50mg + Amlodipine 5mg;Metoprolol XL 25 mg + Amlodipine 2.5mg;Metoprolol XL 50mg;Metoprolol XL 25 mg;Amlodipine 5mg
34 CLEAR: Cylos Pacemaker Responds With Physiologic Rate Changes During Daily Activities Completed NCT00355797 Phase 4
35 HIV Diagnosis and Treatment at Birth for HIV Exposed Newborn Whose Mother Was Not Treated With Antiretroviral Therapy (ART) During Last Month Before Delivery : Strategy Evaluation in Guinea. Completed NCT03642704 Phase 4 Reinforced preventive ARV therapy
36 Physiological Study of the Human CYP3A Activity (PiSA) Completed NCT03204578 Phase 4 AB (Midazolam OD formulation/Dormicum);BA (Dormicum/Midazolam OD formulation)
37 A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea Completed NCT02292290 Phase 4 Liraglutide;Liraglutide;Sulfonylurea or Pioglitazone;Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
38 An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris. Completed NCT00437151 Phase 4
39 STRATEGIES FOR BONDING TO ENAMEL USING A UNIVERSAL ADHESIVE ON SELF-ETCHING MODE Completed NCT03254693 Phase 4
40 A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus Completed NCT00044460 Phase 4 rosiglitazone
41 A Randomized, Parallel-group, Phase IV Study to Compare the Bronchodilator Efficacy of Tiotropium (18 µg Once Daily [od]) Delivered Via a DISCAIR With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD Completed NCT02541006 Phase 4 Tiotropium 18 mcg
42 A Multicenter Randomized Study to Compare the Efficacy and Safety of Lower Dose Atazanavir /Ritonavir (ATV/r 200/100 OD) Versus Standard Dose (ATV/r 300/100 mg OD) in Combination With 2NRTIs in Well Virology Suppressed HIV-infected Adults Completed NCT01159223 Phase 4 ATV/r
43 Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
44 Trial to Compare the Efficacy and Safety of Levocetirizine 5 mg od and Fexofenadine 120 mg od in Reducing Symptoms of Seasonal Allergic Rhinitis in Grass Pollen Sensitized Adults Completed NCT00542607 Phase 4 levocetirizine dihydrochloride
45 The Impact of Heart Rate on Central Hemodynamics in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker Completed NCT03245996 Phase 4 Atenolol Pill;Nebivolol Pill;Ivabradine Pill
46 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
47 PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial Completed NCT01192035 Phase 4 Efavirenz or Nevirapine;Ritonavir-boosted lopinavir
48 Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study Completed NCT01185743 Phase 4 olanzapine;ziprasidone;placebo
49 Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis Completed NCT00439712 Phase 4 Levocetirizine;Placebo
50 Placebo Controlled Pilot Study on the Efficacy of Levocetirizine 5 mg in Reducing Symptoms, Airway Resistance, and Sleep Impairment in Patients With Persistent Allergic Rhinitis Completed NCT00355771 Phase 4 Levocetirizine;Placebo

Search NIH Clinical Center for Feingold Syndrome 1

Cochrane evidence based reviews: oculodigitoesophagoduodenal syndrome

Genetic Tests for Feingold Syndrome 1

Genetic tests related to Feingold Syndrome 1:

# Genetic test Affiliating Genes
1 Feingold Syndrome 1 29 MYCN
2 Feingold Syndrome 29

Anatomical Context for Feingold Syndrome 1

MalaCards organs/tissues related to Feingold Syndrome 1:

40
Liver, Spinal Cord, Bone, Prostate, Skin, Endothelial, Colon

Publications for Feingold Syndrome 1

Articles related to Feingold Syndrome 1:

(show top 50) (show all 68)
# Title Authors PMID Year
1
Genotype-phenotype correlations in MYCN-related Feingold syndrome. 25 6 57 61
18470948 2008
2
Feingold syndrome associated with two novel MYCN mutations in sporadic and familial cases including monozygotic twins. 57 6 25 61
18671284 2008
3
MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. 6 57 61 25
15821734 2005
4
Expanding the clinical spectrum of MYCN-related Feingold syndrome. 57 6 61
16906565 2006
5
De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. 61 6 25
23495052 2013
6
Growth deficiency in oculodigitoesophagoduodenal (Feingold) syndrome--case report and review of the literature. 25 57 61
15930908 2005
7
Familial syndromic esophageal atresia maps to 2p23-p24. 61 25 57
10677303 2000
8
Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans. 6 25
21892160 2011
9
Autosomal dominant inheritance of abnormalities of the hands and feet with short palpebral fissures, variable microcephaly with learning disability, and oesophageal/duodenal atresia. 57 25
1870095 1991
10
A Feingold syndrome case with previously undescribed features and a new mutation. 61 57
19852433 2009
11
Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: review of genetics and epidemiology. 57 61
16299066 2006
12
Feingold syndrome: clinical review and genetic mapping. 57 61
14518066 2003
13
Imperforate anus in Feingold syndrome. 61 57
10817649 2000
14
Feingold syndrome: report of a new family and review. 57 61
9375923 1997
15
Digital anomalies, microcephaly, and normal intelligence: new syndrome or Feingold syndrome? 61 57
9096751 1997
16
MYCN de novo gain-of-function mutation in a patient with a novel megalencephaly syndrome. 61 25
30573562 2019
17
Growth hormone deficiency, aortic dilation, and neurocognitive issues in Feingold syndrome 2. 25 61
30672094 2019
18
Features of Feingold syndrome 1 dominate in subjects with 2p deletions including MYCN. 61 25
30088856 2018
19
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. 6
25741868 2015
20
A de novo 4.4-Mb microdeletion in 2p24.3 → p24.2 in a girl with bilateral hearing impairment, microcephaly, digit abnormalities and Feingold syndrome. 25 61
22842076 2012
21
Dissection of the MYCN locus in Feingold syndrome and isolated oesophageal atresia. 25 61
21224895 2011
22
Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. 57
12777630 2003
23
Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. 57
12441288 2003
24
Vertebral anomalies in a new family with ODED syndrome. 57
10905665 2000
25
Syndrome of microcephaly, mental retardation, and tracheoesophageal fistula associated with features of Rett syndrome. 57
10641614 2000
26
Sonic hedgehog is essential to foregut development. 57
9731532 1998
27
MODED: microcephaly-oculo-digito-esophageal-duodenal syndrome. 57
9268091 1997
28
Autosomal dominant microcephaly with normal intelligence, short palpebral fissures, and digital anomalies. 57
9217213 1997
29
Syndrome of microcephaly, facial and hand abnormalities, tracheoesophageal fistula, duodenal atresia, and developmental delay. 57
9096752 1997
30
An unusual microcephaly. 57
631836 1978
31
The MYCN Protein in Health and Disease. 25
28358317 2017
32
Deletions and de novo mutations of SOX11 are associated with a neurodevelopmental disorder with features of Coffin-Siris syndrome. 25
26543203 2016
33
Timing, rates and spectra of human germline mutation. 25
26656846 2016
34
Activities of N-Myc in the developing limb link control of skeletal size with digit separation. 25
17360777 2007
35
N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. 25
12381668 2002
36
Identification of N-myc regulatory regions involved in embryonic expression. 25
11756639 2002
37
N-myc translation is initiated via an internal ribosome entry segment that displays enhanced activity in neuronal cells. 25
11420678 2001
38
Clinical and molecular characterizations of 11 new patients with type 1 Feingold syndrome: Proposal for selecting diagnostic criteria and further genetic testing in patients with severe phenotype. 61
33442900 2021
39
A novel mutation in MYCN gene causing congenital absence of the flexor pollicis longus tendon as an unusual presentation of Feingold syndrome 1. 61
32925198 2021
40
Metacarpophalangeal pattern profile analysis for a 3-month-old infant with Feingold syndrome 2. 61
33369046 2021
41
A de novo 13q31.3 microduplication encompassing the miR-17 ~ 92 cluster results in features mirroring those associated with Feingold syndrome 2. 61
32473250 2020
42
Innovative management of severe tracheobronchomalacia using anterior and posterior tracheobronchopexy. 61
30908672 2020
43
Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. 61
29636449 2018
44
A case of Feingold type 2 syndrome associated with keratoconus refines keratoconus type 7 locus on chromosome 13q. 61
28159702 2017
45
GENETIC COUNSELLING IN FEINGOLD SYNDROME AND A NOVEL MUTATION. 61
30204967 2016
46
Expanding the phenotype of feingold syndrome-2. 61
26360630 2015
47
Neurobehavioral Alterations in a Genetic Murine Model of Feingold Syndrome 2. 61
26026879 2015
48
A fourth case of Feingold syndrome type 2: psychiatric presentation and management. 61
25391829 2014
49
Recurrent duodenal atresia: a case report. 61
25330697 2014
50
MicroRNA-17~92 is required for nephrogenesis and renal function. 61
24511118 2014

Variations for Feingold Syndrome 1

ClinVar genetic disease variations for Feingold Syndrome 1:

6 (show all 21)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYCN NM_005378.6(MYCN):c.626dup (p.Ala210fs) Duplication Pathogenic 13897 rs1558534266 GRCh37: 2:16082808-16082809
GRCh38: 2:15942686-15942687
2 MYCNOS , MYCN NM_005378.6(MYCN):c.68_71dup (p.Gln25fs) Duplication Pathogenic 433150 rs1553370260 GRCh37: 2:16082251-16082252
GRCh38: 2:15942129-15942130
3 MYCN NM_005378.6(MYCN):c.900_901TG[1] (p.Val301fs) Microsatellite Pathogenic 433154 rs1553370918 GRCh37: 2:16085724-16085725
GRCh38: 2:15945602-15945603
4 MYCN NM_005378.6(MYCN):c.1061dup (p.Ser355fs) Duplication Pathogenic 433152 rs1553370963 GRCh37: 2:16085884-16085885
GRCh38: 2:15945762-15945763
5 MYCN NM_005378.6(MYCN):c.1103_1104AG[3] (p.Ser369fs) Microsatellite Pathogenic 695119 rs1572221400 GRCh37: 2:16085926-16085927
GRCh38: 2:15945804-15945805
6 MYCN NM_005378.6(MYCN):c.1178G>A (p.Arg393His) SNV Pathogenic 13892 rs104893646 GRCh37: 2:16086002-16086002
GRCh38: 2:15945880-15945880
7 MYCN NM_005378.6(MYCN):c.1177C>A (p.Arg393Ser) SNV Pathogenic 13893 rs104893647 GRCh37: 2:16086001-16086001
GRCh38: 2:15945879-15945879
8 MYCN NM_005378.6(MYCN):c.1181G>A (p.Arg394His) SNV Pathogenic 13894 rs104893648 GRCh37: 2:16086005-16086005
GRCh38: 2:15945883-15945883
9 MYCNOS , MYCN NM_005378.6(MYCN):c.231G>A (p.Trp77Ter) SNV Pathogenic 13895 rs121913667 GRCh37: 2:16082417-16082417
GRCh38: 2:15942295-15942295
10 MYCNOS , MYCN NM_005378.6(MYCN):c.217G>T (p.Glu73Ter) SNV Pathogenic 13896 rs113994115 GRCh37: 2:16082403-16082403
GRCh38: 2:15942281-15942281
11 MYCN NM_005378.6(MYCN):c.1145G>A (p.Arg382His) SNV Pathogenic 13898 rs121913666 GRCh37: 2:16085969-16085969
GRCh38: 2:15945847-15945847
12 MYCN NM_005378.6(MYCN):c.1014C>A (p.Tyr338Ter) SNV Pathogenic 433149 rs367962377 GRCh37: 2:16085838-16085838
GRCh38: 2:15945716-15945716
13 MIR17HG NC_000013.11:g.(?_90698351)_(90699137_?)del Deletion Pathogenic 433155 GRCh37: 13:91350605-91351391
GRCh38: 13:90698351-90699137
14 MYCN NM_005378.6(MYCN):c.1117C>T (p.Arg373Ter) SNV Pathogenic 545970 rs754137452 GRCh37: 2:16085941-16085941
GRCh38: 2:15945819-15945819
15 MYCN NM_005378.6(MYCN):c.964C>T (p.Arg322Ter) SNV Pathogenic 433151 rs759103701 GRCh37: 2:16085788-16085788
GRCh38: 2:15945666-15945666
16 MYCNOS , MYCN NM_005378.6(MYCN):c.134dup (p.Glu47fs) Duplication Likely pathogenic 817596 rs780080562 GRCh37: 2:16082313-16082314
GRCh38: 2:15942191-15942192
17 MYCN NM_005378.6(MYCN):c.1181G>T (p.Arg394Leu) SNV Likely pathogenic 433153 rs104893648 GRCh37: 2:16086005-16086005
GRCh38: 2:15945883-15945883
18 MYCN NC_000002.12:g.15945545_15945546TG[1] Microsatellite Likely pathogenic 829866 rs1572220856 GRCh37: 2:16085667-16085668
GRCh38: 2:15945545-15945546
19 MYCN NM_005378.6(MYCN):c.1171C>A (p.Arg391Ser) SNV Likely pathogenic 975607 GRCh37: 2:16085995-16085995
GRCh38: 2:15945873-15945873
20 MYCNOS , MYCN NM_005378.6(MYCN):c.2T>C (p.Met1Thr) SNV Likely benign 977840 GRCh37: 2:16082188-16082188
GRCh38: 2:15942066-15942066
21 MYCNOS , MYCN NM_005378.6(MYCN):c.-211C>T SNV Benign 695120 rs887665529 GRCh37: 2:16080772-16080772
GRCh38: 2:15940650-15940650

UniProtKB/Swiss-Prot genetic disease variations for Feingold Syndrome 1:

72
# Symbol AA change Variation ID SNP ID
1 MYCN p.Arg393His VAR_031952 rs104893646
2 MYCN p.Arg393Ser VAR_031953 rs104893647
3 MYCN p.Arg394His VAR_031954 rs104893648

Expression for Feingold Syndrome 1

Search GEO for disease gene expression data for Feingold Syndrome 1.

Pathways for Feingold Syndrome 1

Pathways related to Feingold Syndrome 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.07 MIR92A1 MIR20A MIR19B1 MIR19A MIR18A MIR17HG
2 12.05 MIR92A1 MIR363 MIR23B MIR20A MIR19B1 MIR19A
3 11.15 MIR92A1 MIR363 MIR20A MIR19B1 MIR19A MIR18A

GO Terms for Feingold Syndrome 1

Cellular components related to Feingold Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR92A1 MIR363 MIR23B MIR20A MIR19B1 MIR19A
2 extracellular vesicle GO:1903561 9.1 MIR92A1 MIR23B MIR20A MIR19B1 MIR19A MIR17

Biological processes related to Feingold Syndrome 1 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 outflow tract morphogenesis GO:0003151 9.63 MIR20A MIR17HG MIR17
2 negative regulation of gene expression GO:0010629 9.63 MYCN MIR92A1 MIR23B MIR20A MIR19B1 MIR17
3 negative regulation of inflammatory response GO:0050728 9.62 MIR92A1 MIR20A MIR19A FOXF1
4 gene silencing by miRNA GO:0035195 9.61 MIR92A1 MIR363 MIR23B MIR20A MIR19B1 MIR19A
5 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.6 MIR20A MIR17
6 embryonic digestive tract development GO:0048566 9.59 GLI3 FOXF1
7 negative regulation of toll-like receptor signaling pathway GO:0034122 9.58 MIR19A MIR17
8 embryonic digestive tract morphogenesis GO:0048557 9.58 GLI3 FOXF1
9 positive regulation of cardiac muscle cell proliferation GO:0060045 9.58 MIR23B MIR19B1 MIR17HG
10 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.57 MIR92A1 MIR17
11 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.56 MIR19B1 MIR19A
12 miRNA mediated inhibition of translation GO:0035278 9.56 MIR92A1 MIR20A MIR19B1 MIR17
13 negative regulation of inflammatory response to antigenic stimulus GO:0002862 9.55 MIR19B1 MIR19A
14 negative regulation of matrix metallopeptidase secretion GO:1904465 9.54 MIR19B1 MIR19A
15 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.54 MIR20A MIR19B1 MIR19A
16 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.52 MIR20A MIR17
17 positive regulation of metalloendopeptidase activity GO:1904685 9.51 MIR92A1 MIR17
18 positive regulation of B cell receptor signaling pathway GO:0050861 9.49 MIR19A MIR18A
19 cellular response to bacterial lipopeptide GO:0071221 9.48 MIR19B1 MIR19A
20 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.43 MIR20A MIR17
21 negative regulation of sprouting angiogenesis GO:1903671 9.1 MIR92A1 MIR23B MIR20A MIR19A MIR18A MIR17

Molecular functions related to Feingold Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR92A1 MIR363 MIR23B MIR20A MIR19B1 MIR19A

Sources for Feingold Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....